IgA Nephropathy Market is expected to grow at a 7.5% CAGR from 2023 to 2033 | FMI Analyst

According to Future Market Insights, the IgA Nephropathy Market is predicted to increase at a 7.5% CAGR between 2023 and 2033. By the year 2033, the global market for IgA nephropathy is predicted to reach a value of US$ 85 billion.

Key factors such as the high frequency of renal illnesses, expanding R&D efforts, increased investments by market participants, and technological breakthroughs are expected to drive market expansion substantially. Furthermore, the rising number of government efforts to provide different services, such as payment for diagnostic tests, is a key driver projected to increase the market.

The COVID-19 pandemic has been associated with increase in hospitalization and infection hotspots around the country. There were at least three separate waves of COVID-19 around the world by June 2021 that put a significant strain on hospital resources, especially labor and availability of dialysis equipment & supplies.

Get a Full PDF Sample Copy of the Latest Reports @ https://www.futuremarketinsights.com/reports/sample/rep-gb-16217

In addition, the COVID-19 pandemic has affected healthcare services for renal disease patients. Social distancing and lockdown were mandate norms, globally, leading to temporary closure of other medical services. The diagnosis of several renal diseases deferred during the pandemic due to suspension of non-urgent visits and testing services.

On the other hand, increasing awareness regarding IgA nephropathy is expected to create lucrative opportunities for the market growth. For instance, In the U.S., an estimated 37 million adults have kidney disease. Major risk factors for the disease are high blood pressure and diabetes as well as heart disease, obesity, & family history of kidney disease. In addition, North America and Asia Pacific are two major regions contributing to the IgA nephropathy market.

Key Takeaways from the Market Study

• IgA Nephropathy market to garner US$ 85 Billion by the end of 2033.
• IgA Nephropathy market to register a positive CAGR of 7.5% in the forecast period 2023-2033
• By end user, the hospital’s segment is expected to hold 40% of the market share in 2023 for IgA nephropathy market.
• By diagnosis, the urine tests segment is projected to witness significant a CAGR of 7.5% during the forecast years.
• North America is expected to possess 40% market share for IgA nephropathy market in 2023.
• Asia Pacific is expected to hold 35% market share for IgA nephropathy market share in 2023.

Speak to our Research Expert @ https://www.futuremarketinsights.com/ask-question/rep-gb-16217

“Growing prevalence of kidney related problems along with research and development for manufacturing medication is favoring the growth of IgA nephropathy market” states a FMI analyst

Competitive Landscape

• In June 2021, Novartis Pharmaceuticals announces iptacopan met Phase II study primary endpoint in rare kidney disease IgA nephropathy (IgAN).
• Chinook Therapeutics, Inc, a key player in the IgA nephropathy market is focusing on diagnosing the causes of the ailment and offering customized and specific treatments based on the same.

Key Companies Profiled:

• Calliditas Therapeutics AB
• Travere Therapeutics, Inc.
• Omeros Corporation
• Novartis Pharmaceuticals
• Chinook Therapeutics, Inc.
• Vera Therapeutics, Inc.
• Otsuka Pharmaceutical
• Alembic Pharmaceuticals Limited
• Teva Pharmaceutical Industries Ltd.
• Johnson & Johnson Private Limited

For more Report Customization, connect with us @ https://www.futuremarketinsights.com/customization-available/rep-gb-16217

Key Segments Profiled in the IgA Nephropathy Market Survey

Diagnosis:

• Iothalamate Clearance Test
• Kidney Biopsy
• Blood Tests
• Urine Tests

Diseases Type:

• Primary IgA Nephropathy
• Secondary IgA Nephropathy

Systems:

• Hematuria
• Proteinuria
• Edema
• Others

Population Type:

• Pediatrics
• Adults

Route of Administration:

• Oral
• Parenteral
• Others

Treatment:

• Medication
• Statin therapy
• Omega-3 fatty acids
• Angiotensin-converting enzyme (ACE) inhibitors
• Angiotensin receptor blockers (ARBs)
• Diuretics
• Immunosuppressants
• Kidney Transplantation
• Others

End Users:

• Hospitals
• Specialty Clinics
• Homecare
• Others

About Future Market Insights (FMI) 

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact:

Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs